Stock Price
44.06
Daily Change
-5.43%
Yearly
276.26%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 19.40 0.61 3.25% -63.66%
Adamas Pharmaceuticals 8.22 0.06 0.74% 91.16%
Agios Pharmaceuticals 32.66 -1.56 -4.56% -25.42%
Akebia Therapeutics 2.54 0.02 0.79% -16.45%
ALKERMES 22.20 0.16 0.73% 18.53%
Alnylam Pharmaceuticals 177.00 5.64 3.29% 39.58%
Alexion Pharmaceuticals 182.50 0 0% 70.54%
Amgen 208.79 6.35 3.14% -7.80%
Biogen 224.11 0.19 0.08% -8.03%
Bluebird Bio 10.01 0.06 0.60% -77.95%
BioMarin Pharmaceutical 84.24 1.29 1.56% 7.46%
Exelixis 16.18 0.34 2.15% -14.16%
Five Prime Therapeutics 38.00 0 0% 1,339.39%
GW Pharmaceuticals 218.96 0 0% 108.53%
Intercept Pharmaceuticals 16.18 0.55 3.52% -52.29%
Incyte Corp 65.01 -0.77 -1.17% -21.73%
Ionis Pharmaceuticals 27.50 1.11 4.21% -46.31%
Intra Cellular Therapies 35.20 -1.11 -3.06% 38.09%
MacroGenics 16.73 0.33 2.01% -27.73%
Neurocrine Biosciences 80.69 1.01 1.27% -11.40%
Nektar Therapeutics 11.86 1.03 9.51% -31.60%
Prothena 44.06 -2.53 -5.43% 276.26%
Ultragenyx Pharmaceutical 78.89 2.88 3.79% -39.28%
Regeneron Pharmaceuticals 625.00 -10.16 -1.60% 26.16%
Seattle Genetics 146.01 -4.73 -3.14% -18.54%
Vertex Pharmaceuticals 205.06 1.25 0.61% -9.69%
Immunic Inc. 8.33 0.01 0.12% -53.90%
Xoma 21.17 0.79 3.88% -40.55%

Indexes Price Day Year
NASDAQ 15225 139.68 0.93% 21.61%
US2000 2203 44.17 2.05% 16.51%

Prothena
Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.